PHARMACEUTICAL DEVOLOPMENT OF A MEDICINAL PRODUCT CONTAINING AN ISOCITRATE LYASE INHIBITOR
Multidrug-resistant tuberculosis remains a critical global health challenge, necessitating novel therapeutic targets. Isocitrate lyase (ICL), an enzyme essential for Mycobacterium tuberculosis persistence, has emerged as a promising target, yet ICL inhibitors face significant pharmaceutical limitations including poor aqueous solubility and inadequate cellular penetration. Objective: To systematically evaluate pharmaceutical formulation strategies addressing the delivery challenges of ICL inhibitors and assess their potential for therapeutic application. Methods: A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Chemical Abstracts Service (January 2000–August 2025) using PRISMA guidelines. Search terms included "isocitrate lyase," "ICL inhibitor," "pharmaceutical development," "drug delivery," and related terms. Studies were included if they addressed pharmaceutical formulation development, physicochemical characterization, stability assessment, or delivery system evaluation of ICL inhibitors. Data were extracted on formulation types, analytical methods, and performance characteristics. Results: Forty-three studies met inclusion criteria. Nano-based delivery systems predominated (58.1%), with polymeric nanoparticles most frequently investigated (42.8%). Surface-modified nanoparticles, particularly mannose-coated formulations, achieved superior macrophage targeting (68.9 ± 7.1% uptake efficiency) and intracellular accumulation (1032.4 ± 94.7 ng/10^6 cells) compared to unmodified carriers. Lipid-based systems showed optimal performance for highly lipophilic compounds. Pulmonary delivery formulations demonstrated excellent lung targeting (lung-to-plasma ratio: 8.5–15.7). Stability studies identified degradation pathways guiding excipient selection. Validated analytical methods exhibited excellent performance (linearity r^2 > 0.999, precision RSD < 2%). Conclusion: Advanced formulation strategies, particularly targeted nanoparticles and pulmonary delivery systems, successfully address pharmaceutical limitations of ICL inhibitors. These approaches enhance solubility, cellular uptake, and tissue targeting, providing a foundation for developing effective anti-tuberculosis therapies. Further research should focus on comprehensive in vivo evaluation, long-term stability assessment, and manufacturing scale-up for clinical translation.
Сведения
- Опубликовано
- 2026 · Т. 466, № 1
- Язык
- Английский
- ISSN
- 2224-5286 · 2518-1491
- Издатель
- Central Asian Academic Research Center LLP